MedTrace Logo

JACTAX LD Drug Eluting Stent Trial

NCT00754975 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2017-03-01

No results posted yet for this study

Summary

Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.

Conditions

Interventions

DEVICE

JACTAX LD DES

Drug Eluting Stent

DEVICE

TAXUS™ Libertè™ DES

Drug Eluting Stent

Sponsors & Collaborators

  • Labcoat, Ltd.

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Eberhard Grube · Elizabeth Hospital, Essen Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-05-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754975 on ClinicalTrials.gov